Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) SEC filings page on Stock Titan provides structured access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, Catalyst uses its filings to report on financial performance, material events, capital allocation decisions, and developments affecting its product portfolio, including FIRDAPSE, AGAMREE, and FYCOMPA.
Investors can review current reports on Form 8-K, where Catalyst discloses events such as quarterly financial results, authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, changes to clinical practice guidelines referencing Lambert-Eaton myasthenic syndrome and amifampridine, and updates to its Board of Directors. These filings often incorporate press releases as exhibits, providing additional context on how specific events may influence the company’s operations and CPRX stock.
In addition to event-driven 8-Ks, users can access periodic reports like Forms 10-Q and 10-K, which contain detailed discussions of product revenue, research and development spending, selling and administrative costs, and other aspects of Catalyst’s business. For a biopharmaceutical issuer, these reports are key resources for understanding revenue contributions from individual products, the status of rare disease programs, and the company’s approach to intellectual property and litigation.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify items such as revenue trends, material agreements, or litigation outcomes. The platform also surfaces insider transaction reports on Form 4 when available, giving additional visibility into trading activity by officers and directors. With real-time updates from EDGAR and simplified explanations of complex regulatory documents, this CPRX filings page supports efficient, in-depth analysis of Catalyst Pharmaceuticals’ regulatory record.
Catalyst Pharmaceuticals (CPRX) reported equity transactions by its Chief Strategy Officer on a Form 4. On 11/21/2025, the officer acquired 5,603 shares of common stock through the exercise of derivative awards and had 1,364 shares withheld to cover taxes, leaving 45,320 shares of common stock owned directly.
The filing also shows new derivative awards dated 11/20/2025, including options to purchase 106,873 shares of common stock at an exercise price of $22.77 per share and 32,257 restricted stock units (RSUs). The options and RSUs generally vest in three equal annual tranches from November 20, 2026 through November 20, 2028. Additional RSUs that vest in thirds each year from November 21, 2025 to November 21, 2027 are also reported.
Catalyst Pharmaceuticals (CPRX) reported insider equity activity by its Chief Operating and Scientific Officer on a Form 4. On November 20, 2025, the officer received options to purchase 158,454 shares of common stock at an exercise price of $22.77 per share. These options vest in three equal installments on November 20, 2026, November 20, 2027, and November 20, 2028.
Also on November 20, 2025, the officer was granted 47,826 restricted stock units (RSUs), with shares delivered upon vesting. A separate RSU award vests in three equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027, and shares must be delivered within sixty days of each vesting date; the first tranche of 8,267 shares was delivered on November 21, 2025. Following these transactions, the officer directly owned 1,067,930 shares of common stock.
Catalyst Pharmaceuticals (CPRX) reported an equity compensation grant to its Chief HR Officer on November 20, 2025. The officer received options to purchase 20,531 shares of common stock at an exercise price of $22.77 per share, along with 6,197 restricted stock units (RSUs). The options vest in three equal annual installments, with one-third vesting on November 20, 2026, one-third on November 20, 2027, and one-third on November 20, 2028. Each RSU represents a right to receive one share of common stock upon vesting, and shares will be delivered to the officer when the RSUs vest. Following these awards, the officer beneficially owns 66,276 options and 72,473 RSUs in total.
Catalyst Pharmaceuticals (CPRX) reported insider equity awards for a director on a Form 4. On November 20, 2025, the reporting person received options to purchase 18,115 shares of common stock at an exercise price of $22.77, and 5,468 restricted stock units (RSUs). On November 21, 2025, 947 RSUs were settled in common stock, increasing the director’s directly held common shares to 2,360.
Following these transactions, the director held 116,555 stock options, 121,076 RSUs, and 2,360 shares of common stock, all directly. The options and RSUs generally vest in three equal annual tranches on specified dates in 2025, 2026, 2027, and 2028, with shares required to be delivered within sixty days of vesting.
Catalyst Pharmaceuticals Executive Vice President and CFO Michael W. Kalb reported equity award activity in company stock. On 11/21/2025, he acquired 6,894 shares of common stock through an option exercise (code M) and had 2,485 shares withheld to cover taxes on vesting (code F), leaving him with 8,606 shares of common stock held directly.
He was granted options to purchase 131,536 shares at an exercise price of $22.77 per share, expiring on 11/20/2032. These options vest in three equal annual tranches on November 20, 2026, November 20, 2027, and November 20, 2028. He also received 39,701 restricted stock units, which convert into common shares upon vesting, and additional RSU-related vesting of 6,894 shares scheduled in equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027.
Catalyst Pharmaceuticals, Inc. (CPRX) director David S. Tierney reported equity awards and a share delivery around late November 2025. On 11/20/2025, he was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, vesting in three equal annual installments on November 20, 2026, 2027, and 2028. He was also granted 5,468 restricted stock units (RSUs), which convert into the same number of common shares upon vesting on the same three-year schedule.
On 11/21/2025, 947 RSUs were settled into common stock, adding 947 shares of common stock to his direct holdings and reducing his derivative balance. After these transactions, he directly owned 380,567 shares of common stock and held 180,910 derivative securities, including options and RSUs, all reported as directly owned.
Catalyst Pharmaceuticals, Inc. (CPRX) reported an insider equity award for its Chairman of the Board and Director, Patrick J. McEnany. On 11/20/2025, he received options to purchase 34,921 shares of common stock at an exercise price of $22.77 per share, along with 10,540 restricted stock units (RSUs). The options and RSUs generally vest in three equal annual installments on November 20 of 2026, 2027, and 2028.
On 11/21/2025, 1,775 RSUs were settled, and McEnany acquired 1,775 shares of common stock, increasing his directly held common stock to 4,283,477 shares. Following these transactions, he also beneficially owned 1,881,816 derivative securities, including options and RSUs that will deliver common shares as they vest and are settled.
Catalyst Pharmaceuticals, Inc. (CPRX) reported an insider equity transaction by a director. The filing shows the acquisition of 947 shares of common stock, following the exercise or settlement of equity awards, bringing the director’s directly held common stock position to 7,693 shares.
The director was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. In addition, the director received 5,468 restricted stock units (RSUs), each representing a right to one share of common stock upon vesting. These options and RSUs generally vest in three equal annual tranches on November 20, 2026, November 20, 2027, and November 20, 2028, with a separate RSU grant vesting in equal parts on November 21, 2025, November 21, 2026, and November 21, 2027.
Catalyst Pharmaceuticals (CPRX) President and CEO Richard J. Daly, who also serves as a director, reported new equity awards and related share activity. On November 21, 2025, he acquired 20,006 shares of common stock through the vesting of restricted stock units and had 7,872 shares withheld to cover taxes, leaving him with 238,928 shares of common stock held directly.
On November 20, 2025, he received options to purchase 381,948 shares of common stock at an exercise price of $22.77 per share, vesting in three equal annual tranches on November 20, 2026, November 20, 2027, and November 20, 2028. He was also granted 115,283 restricted stock units that vest on the same schedule. Following these transactions, Daly beneficially owns 2,661,978 derivative securities tied to Catalyst common stock.
Catalyst Pharmaceuticals (CPRX) director reports equity awards and vesting activity. A board member filed a Form 4 disclosing equity-based compensation and related share delivery in November 2025.
The reporting person was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 on November 20, 2025. These options vest in three equal annual installments on November 20 of 2026, 2027, and 2028. The filing also shows an award of 5,468 restricted stock units (RSUs) on November 20, 2025, each convertible into one share upon vesting.
On November 21, 2025, 947 RSUs were converted, and the corresponding 947 common shares were delivered to the director. Following these transactions, the director reports beneficial ownership of 496,026 shares of Catalyst Pharmaceuticals common stock directly, along with derivative holdings consisting of options and RSUs that will deliver additional shares as they vest over time.